The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

The US Food and Drug Administration (FDA) has accepted for review Regeneron Pharmaceuticals’ resubmission of the Biologics ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...

The London Company, an investment management company, released “The London Company Mid Cap Strategy” fourth quarter 2024 ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

US biotech Regeneron Pharmaceuticals says that its investigational gene therapy DB-OTO showed clinically-meaningful hearing ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

All absentee ballots must be submitted by 5 p.m. on May 20. The district also used the board meeting to celebrate its Regeneron Science Talent Search finalist, Sandeep Sawhney, and to recognize ...